TF and neoplasm: Importantly, ablation of CD44v6 or ESRP1 with our CD44vshRNA/Tf-PEG-PEI-nanoparticles or ESRP1shRNA/Tf-PEG-PEI-nanoparticles will have important potential to reduce tumor growth that involves overexpression of CD44v or ESRP1, indicating the importance of tissue specific delivery of shRNA/nanoparticle technology.